SLC5A2 and chronic kidney disease: Moreover, the KDIGO 2022 Clinical Practice Guidelines for Diabetes Management in CKD recommend the use of SGLT2 inhibitors for most patients with T2DM, CKD and an eGFR ≥ 20 mL/min per 1.73 m2 [8,9].